Heska Corporation

Heska Corporation

HSKA

$119.99

Updated: 22/09/2026, 18:14:31

Market Cap
$1.31B
Sector
Healthcare
Industry
Medical - Devices
Country
US

No historical data available

Company Profile

Heska Corporation provides specialized diagnostic and animal health products, predominantly for canine and feline veterinary care markets in the United States, Canada, Mexico, Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. Its product line includes a variety of veterinary chemistry analyzers: the Element DC, DCX, and DC5x series, along with the Element RC, RCX, and RC3X systems, all tailored for blood chemistry and electrolyte analysis. For hematological assessments, Heska offers the Element HT5 and scil Vet abc Plus analyzers, capable of measuring blood cell and platelet counts, as well as hemoglobin levels. The company also supplies Element POC analyzers for blood gas and electrolyte testing, Element i immunodiagnostic analyzers, and the Element COAG and Element AIM veterinary analyzers for coagulation studies. Beyond analytical instruments, Heska's offerings extend to advanced imaging and clinical solutions such as HeskaView Telecytology, which provides automated microscopic slide scanning equipment for clinics, and IV infusion pumps. They also distribute digital radiography hardware, including mobile units, sophisticated ultrasound systems, and Cloudbank, a web-based platform for image storage. For rapid, in-clinic detection, point-of-care products are available to identify antigens and antibodies associated with infectious and parasitic diseases in animals. Therapeutic options include Tri-Heart Plus chewable tablets for treating canine heartworm, ascarid, and hookworm infections. The company also specializes in allergy management, offering ALLERCEPT definitive allergen panels for diagnosis and personalized therapy shots or drops. Furthermore, Heska develops a range of vaccines for bovine health. It supplies biological and pharmaceutical products to other animal health companies and offers comprehensive turnkey services encompassing research, licensing, production, labeling, packaging, validation support, and distribution. Products are distributed to veterinarians via a direct telephone sales force, third-party distributors, trade shows, print advertisements, and other strategic partnerships. Founded in 1988, the company was initially known as Paravax, Inc. before rebranding as Heska Corporation in 1995. Its corporate headquarters are located in Loveland, Colorado.

USD
NASDAQ
CEO: Kevin S. Wilson
Employees: 808
https://www.antechdiagnostics.com/in-house-diagnostics
Asset Summaries
Latest generated summaries for HSKA

No summaries found.

Detailed business
Structured knowledge from the latest official annual filing.
No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.
Full company information
Latest profile, trading, valuation, and identifier data stored for HSKA.
Share price
$119.99
Market cap
$1.31B
Exchange
NASDAQ
Currency
USD
CEO
Kevin S. Wilson
Employees
808
IPO date
01/07/1997
Beta
1.599225
Last dividend
$0.00
Day range
$119.99 – $119.99
52-week range
$57.83 – $120.03
1-day performance
0.00%
1-year performance
107.49%
Current drawdown (1Y)
-0.03%
CIK
0001038133
CUSIP
42805E306
ISIN
US42805E3062
Created
07/12/2025, 04:36:10
Last update
22/09/2026, 18:14:31

Track Heska Corporation with an AI analyst

See which prediction-market events move HSKA, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News
News linked to HSKA from your Railway `news_articles` table.

No news found for this symbol.